ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Questionnaire
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Account
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Press
August 6, 2024
28 Aug 2023

Acarix välkomnar Dr. Deepak R. Talreja MD som ny medicinsk rådgivare

Acarix, ledande inom akustisk och AI-baserad hjärtdiagnostik, tillkännager idag utnämningen av Dr. Deepak R. Talreja, MD, som ny medici...
Continue reading
author-avatar acarix
Press
August 6, 2024
23 Aug 2023

Acarix to participate in Erik Penser Bank’s Company Day on August 24, 2023

Acarix, a leader in acoustic and AI-based cardiac diagnostics, is pleased to announce participation in the upcoming Erik Penser Bank Co...
Continue reading
author-avatar acarix
Press
August 6, 2024
23 Aug 2023

Acarix deltar på Erik Penser Banks Bolagsdag den 24 augusti 2023

Acarix, ledande inom akustisk och AI-baserad hjärtdiagnostik, meddelar sitt deltagande i den kommande Erik Penser Banks Bolagsdag den 2...
Continue reading
author-avatar acarix
Press
August 6, 2024
09 Jun 2023

Announcement from Acarix’s extra general meeting

The extra general meeting of Acarix AB (the "Company") was held today on 9 June 2023 and the following resolutions were passe...
Continue reading
author-avatar acarix
Press
August 6, 2024
09 Jun 2023

Kommuniké från extra bolagsstämma i Acarix

Extra bolagsstämma i Acarix AB ("Bolaget") hölls idag den 9 juni 2023 varvid aktieägarna fattade följande beslut. Beslut om g...
Continue reading
author-avatar acarix
Press
August 6, 2024
22 May 2023

Notice of Extra General Meeting in Acarix AB

The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby invited to the extra general meeting to be h...
Continue reading
author-avatar acarix
Press
August 6, 2024
22 May 2023

Kallelse till extra bolagsstämma i Acarix AB

Aktieägarna i Acarix AB, org.nr 559009-0667, ("Bolaget") kallas härmed till extra bolagsstämma fredagen den 9 juni 2023 kl. 1...
Continue reading
author-avatar acarix
Press
August 6, 2024
22 May 2023

Acarix raises approximately SEK 22 million through exercise of warrants and resolves on a directed share issue

In December 2022, Acarix AB (publ) (“Acarix” or the “Company”) carried out a rights issue of shares and warrants of series 2022:U (the ...
Continue reading
author-avatar acarix
Press
August 6, 2024
22 May 2023

Acarix tillförs cirka 22 MSEK genom utnyttjandet av teckningsoptioner och beslutar om riktad nyemission

Acarix AB (publ) (“Acarix” eller “Bolaget”) genomförde under december 2022 en företrädesemission av aktier och teckningsoptioner av ser...
Continue reading
author-avatar acarix
Press
August 6, 2024
17 May 2023

State-of-the-Art Cardiology Clinic enhances patient care with CADScor System

Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces today that Abo-Auda Associates Cardiologists in Texoma, Texas ...
Continue reading
author-avatar acarix
Press
August 6, 2024
17 May 2023

State-of-the-Art kardiologiklinik förbättrar patientvården med CADScor System

Acarix, ledande inom akustisk och AI-baserad hjärtdiagnostik, meddelar idag att Abo-Auda Associates Cardiologists i Texoma, Texas komme...
Continue reading
author-avatar acarix
Press
August 6, 2024
16 May 2023

Acarix tilldelas Business Sweden 2023 Catalyst Program Award

Acarix, ledande inom akustisk och AI-baserad hjärtdiagnostik, har nöjet att meddela tilldelningen av 2023 Catalyst Program Award inom L...
Continue reading
  • «
  • ‹
  • 8
  • 9
  • 10
  • 11
  • 12
  • ›
  • »
Acarix AB
Jungmansgatan 12
211 19 Malmö
SE
[email protected]

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • Press
  • Events
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V5

  • Products
    • Background
    • What is Coronary Artery Disease
    • Diagnosing CAD
    • About the product
    • The Cadscor System
    • How Does it Work
  • Resources
    • Testimonial
    • HCP Stories
    • Patients Stories
    • References
    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Support
    • Training
    • Faq
    • Reimbursement
    • Physician Locator
    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
    • About Acarix
    • Leadership
    • Join The Team
    • Get in touch
    • Contact Us
    • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.